Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis Seagen Inc. SGEN

Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.


Opinion & Analysis (NDAQ:SGEN)

    Seattle Genetics Shares Trade Higher on Q1/20 Earnings and 22% Growth in ADCETRIS Sales

    Streetwise Reports May 4, 2020

    Biotech's Topline Breast Cancer Data Impresses

    Streetwise Reports October 24, 2019

    Seattle Genetics Shares Head Higher After Positive Earnings and ADCETRIS Sales Expansion

    Streetwise Reports July 19, 2019

    CAR T-cell therapeutics: Alan Leong of BioWatch looks beyond the buzz for solid early-stage plays

    Gail Dutton September 10, 2015

    Buy biotech when there's blood on the street: Pontifax's Ran Nussbaum

    George S. Mack September 3, 2015

    New Biotech ETF From ALPS

    Benzinga.com  January 2, 2015